iwAL 2026 | KOMET-007 trial results: ziftomenib combinations in NPM1-mutated and KMT2A-rearranged AML
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses findings from the KOMET-007 study (NCT05735184) evaluating ziftomenib in combination with intensive chemotherapy or azacitidine and venetoclax in acute myeloid leukemia (AML). He highlights high remission rates in NPM1-mutated and KMT2A-rearranged AML, as well as promising results with azacitidine and venetoclax in patients ineligible for intensive induction. This interview took place at the 8th International Workshop on Acute Leukemias (iwAL 2026), held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We’ve been involved with the KOMET-007 study, which looked at various combinations with the menin inhibitors, ziftomenib, including standard azacitidine and venetoclax for induction ineligible patients, as well as intensive induction for the eligible patients. The data that’s been emerging from recent meetings has shown fairly impressive results, including very high composite remissions for NPM1-mutated patients on the intensive group of patients, as well as impressive results for KMT2A-rearranged patients undergoing a combination of ziftomenib in intensive induction chemotherapy...
We’ve been involved with the KOMET-007 study, which looked at various combinations with the menin inhibitors, ziftomenib, including standard azacitidine and venetoclax for induction ineligible patients, as well as intensive induction for the eligible patients. The data that’s been emerging from recent meetings has shown fairly impressive results, including very high composite remissions for NPM1-mutated patients on the intensive group of patients, as well as impressive results for KMT2A-rearranged patients undergoing a combination of ziftomenib in intensive induction chemotherapy. The follow-up time is relatively brief, but overall it looks like these responses are quite sustainable for KMT2A rearranged patients. Many of them are heading to transplant, which is a curative modality for that disease. More importantly, the azacitidine venetoclax combination also looks quite promising. You have high rates of remission, patients doing well. This is in the upfront setting where you have a higher likelihood of achieving a response and doing quite well. And we are hopeful that this will translate into good results in the upcoming phase three KOMET-017 study, which is starting to enroll patients right now.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
